OOOluchi Okechukwu

Oluchi Okechukwu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oluchi Okechukwu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical Effectiveness and Safety of Pathogen-Reduction Technologies for Platelets and Plasma: A Systematic Review

    by Oluchi Okechukwu, Chidinma Gab-Obinna, Adepeju Kafayat Olowookere, Christopher Bijabdo Jato, Richard Afriyie Osei, Dorcas Okayo Okayo, Tobi David Farinde, Lawrence John Ajutor

    Pathogen-reduction technologies (PRTs) methods for platelet and plasma are increasingly being relied on to inactivate a broad spectrum of pathogens to ensure safety in transfusion. However, there is continuing debate about the impact of such technology on clinical effectiveness, bleeding outcomes, and transfusion-related adverse events. Objective: This systematic review evaluated the clinical effectiveness and safety of PRT-treated platelets and plasma using studies published between 2015 and 2025. Methods: Following PRISMA 2020 guidelines, major databases including PubMed, Scopus, Embase, Web of Science, and Google Scholar were searched for studies published between 2015 and 2025. Eligible studies included human studies, platelet and/or plasma products that have been treated with specific PRT technology. A total of 1256 records were identified. Findings were synthesized narratively and presented descriptively. Results: Fifteen qualifying studies utilizing pathogen-reduced platelets and plasma from various areas were included. In randomized trials, platelets treated with PRT consistently exhibited decreased CCI at both 1 hour and 24 hours compared to conventional platelets, with certain studies indicating greater platelet use. Even though the platelet increments were lower, most trials did not report any significant rise in WHO grade ≥2 clinical bleeding, and the hemostatic efficacy was still satisfactory. Safety outcomes were relatively good: datasets showed that transfusion-reaction rates were low (<1%) and major adverse events were not so common. PRT systems showed strong pathogen-inactivation abilities, including the ability to effectively inactivate clinically important viruses such as hepatitis viruses, dengue, and Japanese encephalitis virus. Different technologies had different results, and UVC-based systems sometimes showed smaller increases after transfusions. Conclusion: Platelets and plasma treated with PRT are still clinically useful and very safe. They also greatly lower the risk of infections that can be spread by transfusions. Even though there are fewer laboratory increments and more platelet use, these changes don't seem to affect clinical hemostasis. Strengthening implementation methods, inventory planning, and hemovigilance systems alongside continuing evaluation of performance will enable safer transfusion procedures and safeguard vulnerable patient groups globally.

  • Next-Generation Sequencing for Minimal Residual Disease Detection in AML: Current Technologies and Clinical Implications.

    by Chidinma Lorretta Gab-Obinna, Ikemefula Oriaku, Oluchi Okechukwu, Adepeju Kafayat Olowookere, Nwamaka Nneka Onyedum, Precious Deborah Ojetunde ‎, Kwesi Egyin Taylor

    Minimal residual disease (MRD) has become a significant predictor of relapse and survival in acute myeloid leukemia (AML), indicating the extent of remission beyond traditional morphological evaluation. Although multicolor flow cytometry and quantitative PCR are essential methodologies in minimal residual disease identification, both are constrained by immunophenotypic variability, the necessity for stable molecular targets, and limited sensitivity. Advancements in next-generation sequencing (NGS) have revolutionized the minimal residual disease (MRD) field by enabling highly sensitive, mutation-driven identification of leukemic clones across a broad genomic landscape. Contemporary error-suppressed next-generation sequencing techniques—such as unique molecular identifiers, duplex sequencing, and single-molecule molecular inversion probes—have enhanced analytical sensitivity to the 10⁻⁵ to 10⁻⁶ range, enabling the detection of ultra-low-frequency variations with greater specificity. These techniques improve clinical risk classification, refine prognostication within genetically defined AML subtypes, and guide therapeutic options, including post-remission therapy, targeted inhibition, and the timing and intensity of allogeneic stem cell transplantation. Innovative applications, such as single-cell sequencing, cell-free DNA studies, and integrative multi-omic MRD evaluation, enhance the capabilities of genomics-based monitoring. Nonetheless, obstacles remain, such as differentiating cancer mutations from clonal hematopoiesis, standardizing analytical pipelines, establishing clinically relevant thresholds, and incorporating NGS MRD into standardized treatment protocols. This review encapsulates contemporary NGS methods for AML MRD diagnosis, assesses their clinical ramifications and constraints, and suggests future pathways necessary for comprehensive clinical integration. With advancements in the area, NGS-based MRD is set to become a pivotal element of precision-guided AML control.

  • Artificial Intelligence in Transfusion Medicine: Current Applications, Opportunities, and Challenges

    by Ikemefula Oriaku, Oluchi Okechukwu, Obiageri Ihuarulam Okeoma, Chidinma Gab-Obinna, Jazuli Isyaku Bala, Adeyinka Moyinoluwa Adejumobi, Oluwabusayo Olufunke Awoyomi

    Artificial intelligence (AI) is increasingly shaping modern healthcare by enabling data-driven decision-making, improving diagnostic accuracy, and optimizing resource use. In transfusion medicine, AI offers substantial opportunities to enhance donor management, automate blood typing and compatibility testing, strengthen inventory forecasting, and support early detection of transfusion-related complications. This review summarizes current applications of AI technologies—including machine learning, deep learning, natural language processing, computer vision, and predictive analytics—and evaluates their impact across laboratory, clinical, and operational domains. Emerging innovations such as precision transfusion, patient digital twins, multi-omics integration, and federated learning highlight AI’s potential to advance personalized and interconnected transfusion practices. However, successful implementation requires addressing challenges related to data heterogeneity, algorithmic bias, privacy and ethical considerations, and evolving regulatory requirements. Establishing rigorous validation standards and promoting interdisciplinary collaboration will be essential to ensure that AI improves the safety, efficiency, and sustainability of transfusion medicine.